Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AdCOVID · 1 trial · 1 indication
Counts and percentages of subjects with local and systemic events
Counts and percentages of subjects with AEs
| Arm | Type | Description |
|---|---|---|
| Single Low Dose AdCOVID | EXPERIMENTAL | - |
| Single Medium Dose AdCOVID | EXPERIMENTAL | - |
| Single High Dose AdCOVID | EXPERIMENTAL | - |
| Two Low Doses AdCOVID | EXPERIMENTAL | - |
| Two Medium Doses AdCOVID | EXPERIMENTAL | - |
| Two High Doses AdCOVID | EXPERIMENTAL | - |
| Single Dose Placebo | PLACEBO_COMPARATOR | - |
| Two Dose Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AdCOVID | BIOLOGICAL | Administered intranasally |
| Placebo | OTHER | Administered intranasally |
Inclusion Criteria: * Men and women ages 18 to 55 years, inclusive * Good general health status * Screening laboratory results within institutional normal range or Grade 1 abnormality if the Investigator documents clinical insignificance. Grade 2 laboratories may be permissible if considered not cl...
AdCOVID is an investigational vaccine being studied for use in healthy volunteers. It was evaluated in a Phase 1 clinical trial to assess its safety and immunogenicity as a potential COVID-19 vaccine. The study enrolled healthy adults aged 18 years and older in the United States.
AdCOVID is being developed by Altimmune, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALT. The company conducted a Phase 1 clinical trial of AdCOVID in healthy volunteers in the United States.
AdCOVID is in Phase 1 clinical development. It has completed a Phase 1 trial, and it remains an investigational drug. It has not been approved by the FDA, and it is still in the clinical development process.
AdCOVID has been studied in one clinical trial, identified as NCT04679909. This was a Phase 1, randomized, double-blind, placebo-controlled study titled 'Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study).' The trial enrolled 92 healthy volunteers in the United States and has been completed.
AdCOVID is classified as a monoclonal antibody modality, though it is being developed as a vaccine. In the clinical trial, it was administered to healthy volunteers to evaluate its safety and ability to generate an immune response against COVID-19.